VTE Prevention Across the Continuum: Applications of Clinical Evidence for Extended Prophylaxis from Inpatient to Outpatient Care

VTE Prevention Across the Continuum: Applications of Clinical Evidence for Extended Prophylaxis from Inpatient to Outpatient Care

On-Demand Webcast

This webcast is based on live proceedings from the Pharmacy Learning Network 2018 Conference Series. 

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.


Mark A Munger, PharmD, FCCP, FACC, FHFSA
Professor, Pharmacotherapy
Adjunct Professor, Internal Medicine
Associate Dean, College Affairs, College of Pharmacy
University of Utah Health Sciences Center
Salt Lake City, Utah

Intended Learners

This activity is designed for pharmacists involved in patient care.

Learning Objectives

After completing this activity, participants should be able to:

  • Quantify the clinical and economic burdens associated with VTE in patients admitted for acute medical illness as well as post-discharge
  • Describe the standard of care for VTE prophylaxis in the acute hospitalization and post-discharge care settings
  • Evaluate the latest clinical evidence associated with the use of DOACs for the acute and extended prophylaxis of VTE, particularly the implications of newly approved factor Xa inhibitors
  • Incorporate risk stratification tools, patient-specific factors, and shared decision-making within the identification of patients who would most benefit from extended VTE prophylaxis
  • Lead the interdisciplinary care team in the management of anticoagulant therapy for VTE prophylaxis, ensuring individualized therapeutic selection, patient-centric education and monitoring, and coordinated transitions of care from hospital to outpatient settings
Activity Overview

This on-demand webcast is available with synchronized slides and video.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Release Date: September 28, 2018
Expiration Date: September 28, 2019
Estimated time to complete: 45 minutes

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.


  In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


This activity is approved for .75 contact hour (.075 CEU) of continuing pharmacy education (JA0006201-0000-18-181-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Kyle R. Copeland, PharmD, Clinical Specialist Pharmacist, Parkwest Medical Center, Assistant Professor, University of Tennessee College of Pharmacy, Knoxville, Tennessee

Planning Committee

The planning committee comprises Mark A Munger, PharmD, FCCP, FACC, FHFSA, Kyle R. Copeland, PharmD; and Donna Brophy, Celeste Collazo, Molly Duda, Mary Johnson, Michael Kearney,  and Randy Robbin, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty have disclosed the following:

Dr. Copeland and Dr. Munger disclosed no relevant financial relationships with any commercial interests.

Ms. Brophy, Ms. Browne, Ms. Collazo, Ms. Duda, Ms. Johnson, Mr. Kearney, Mr. Robbin, Ms. Yarborough have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved uses of drugs and/or devices will be discussed.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.